RxDoctor Payments Data

Vijay Patel, MD

Family Medicine · Wayne, MINPI 1275678948

Payments from drug & device makers

$1,210in general payments, 2019–2025

Across 17 payments — averaging $71.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$627
  • Abbott$134
  • Teva Pharmaceuticals USA, Inc.$118
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$96
  • AstraZeneca$66
  • Astellas Pharma US Inc$62
  • plus $107 from 5 others

What the payments were for

  • Travel & lodging$55546%
  • Food & beverage$65554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,210 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$57,296
Medicare patients
127
Services billed
672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin86$94,812
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$59,961
EliquisApixaban69$48,760
MounjaroTirzepatide31$32,227
FarxigaDapagliflozin Propanediol35$25,572
LinzessLinaclotide32$19,564
XareltoRivaroxaban19$13,728
OzempicSemaglutide14$12,569
Spiriva HandihalerTiotropium Bromide12$8,937
BrilintaTicagrelor13$8,549
Breo ElliptaFluticasone/Vilanterol20$7,769
Albuterol Sulfate HfaAlbuterol Sulfate152$5,285
Novolog FlexpenInsulin Aspart20$3,418
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,291
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$48,76069 claims
AstraZenecaFarxiga, Brilinta$66$34,12048 claims
Novo NordiskOzempic$15$12,56914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Wayne

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →